首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1624427

2024 年至 2031 年生物銀行市場類型、應用、樣本類型和地區

Biobanking Market By Type (Equipment, Consumables, Services, Software), By Application (Life Science Research, Regenerative Medicine), By Sample Type (Blood Products, Human Tissues, Nucleic Acids) & Region For 2024-2031

出版日期: 2024年11月16日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

生物庫市場評估，2024-2031

基因組學、個人化醫療和生物技術日益重要，推動了對用於研發的高品質生物樣本的需求。慢性病的增加，加上個人化醫療需求的不斷增長，推動了對生物庫的需求。此外，公共和私營部門的資金增加、大型生物庫的建立以及儲存和保存技術的進步也促進了市場的成長。此外，將生物庫與大數據和人工智慧結合，以實現更有效的數據分析和利用，也對於產業的發展至關重要。預計生物銀行市場收入將在 2023 年超過 10.6546 億美元，到 2031 年將達到 21.1762 億美元。

此外，現代生物庫越來越多地使用自動化和數位化來提高樣本收集、儲存和資料管理的效率。冷凍保存和分子生物學程序的進步提高了保存的生物資源的品質和耐久性。此外，生物資訊學和數據分析的改進使得生物庫樣本能夠更有效地用於研究和臨床應用。確保道德標準和資料保護的監管框架也在不斷發展，從而增加了社會對生物銀行工作的信任和參與。預計 2024 年至 2031 年期間市場複合年增長率為 9.89%。

生物庫市場定義/概述

現代生物庫越來越多地使用自動化和數位化來提高樣本收集、儲存和資料管理的效率。冷凍保存和分子生物學程序的進步提高了保存的生物資源的品質和耐久性。此外，生物資訊學和數據分析的改進使得生物庫樣本能夠更有效地用於研究和臨床應用。確保道德標準和資料保護的監管框架也在不斷發展，從而增加了社會對生物銀行工作的信任和參與。這種情況的融合使得生物庫成為改善科學研究和醫療保健結果的關鍵組成部分。生物庫的未來潛力是巨大的和變革性的，對個人化醫療、遺傳學和公共衛生具有重要意義。隨著生物庫的擴大，它們可以透過提供高品質、多樣化的生物樣整體支持大規模研究項目，從而更深入地瞭解疾病機制、基因突變和治療反應。整合人工智慧和大數據分析等新技術將提高我們檢測生物標記和設計標靶治療的能力。此外，生物庫可以促進國際合作，加強疾病監測，有助於預防性保健措施，並提供更有效和個人化的醫療介入。

基因體學和精準醫療的進步是否會導致生物庫市場的成長？

基因組學和精準醫療的不斷進步將極大地推動生物銀行市場的擴張。基因組學和精準醫療依賴高品質的生物樣整體更好地瞭解基因變異及其對健康和疾病的影響。生物庫提供了儲存和管理這些樣本的必要基礎設施，使其可用於研究和治療。

標靶治療的開發旨在根據特定的基因特徵制定治療方案。需要對疾病的遺傳基礎進行廣泛的研究，這需要獲取生物庫中儲存的大量且特徵明確的生物樣本。隨著越來越多定製藥物的開發，對生物庫服務的需求正在增加。下一代定序（NGS）和其他基因組技術等定序技術的進步大大降低了基因分析的成本和時間。這些技術產生的大量數據必須與正確註釋的生物樣本連結。生物庫在這過程中發揮關鍵作用，因為它們提供了大規模基因組研究所需的樣本和數據。

此外，生物庫透過提供來自不同人群的大量隊列樣本，促進了基因組研究和疾病知識的進步。這種支持對於確定疾病的遺傳基礎、發現生物標記和創建預測模型至關重要。隨著基因組研究的擴展，強大的生物庫基礎設施變得越來越重要。精準醫療需要將基因組數據與臨床資訊結合，才能全面瞭解患者的健康狀況。生物庫經常將生物樣本與臨床數據聯繫起來，使研究人員能夠將遺傳資訊與健康結果關聯起來。這種整合對於制定客製化治療方案至關重要，從而增加了對生物銀行服務的需求。

此外，基因組學和精準醫學的進步經常需要監管和道德支持。改進的監管和道德框架將確保生物樣本得到適當的收集、儲存和使用。這樣的框架將提高社會對生物庫的信任和參與度，擴大可用的樣本庫，並加強市場。專注於基因組學和精準醫療的全球研究合作和聯盟經常使用生物庫來促進協作、數據共享和彙集資源。這種合作使得大規模研究和快速發現成為可能，增加了改善生物銀行系統的需求。癌症、糖尿病和心血管疾病等慢性病的發生率不斷上升，凸顯了對大量生物庫的需求，以便研究和開發新的治療方法。個人化醫療主要依賴遺傳和分子數據，這需要組織良好的生物庫來提供必要的生物材料。

人們對基因組學和精準醫療的興趣日益濃厚，刺激了商業和研究機構的大量投資。這項投資支持生物庫設施的創建和發展，確保它們配備最新的技術和最佳實踐，以滿足該行業不斷變化的需求。

樣本品質和標準化是否會阻礙生物銀行市場的發展？

不可重複的發現可能是由於樣本品質差，破壞了科學研究的可靠性。如果樣本在採集、處理或儲存過程中受到污染、損壞或管理不善，實驗結果可能會變得不一致和有偏差，使其他研究人員難以重現結果。樣本品質的降低會損害連結資料的完整性，包括臨床、基因組和組學資料。不準確或不完整的數據，加上樣本品質差，會導致錯誤的結論並阻礙科學知識的進步。

此外，生物庫的任務是長期（可能長達數十年）保存樣本，因此必須確保樣本隨時間的完整性和穩定性。必須嚴格控制溫度、濕度和光照等儲存參數，以確保樣品保持活力並代表原始樣本。未能保持適當的儲存條件可能會導致樣品變質不適合下游分析。不同生物庫所採用的程序、協議和設備的差異可能導致樣本品質的差異，從而難以比較不同研究的結果和總結數據。

此外，監管合規和認證是生物銀行的重要組成部分，生物銀行必須遵守監管限制和認證標準，以確保其遵循道德、法律和品質保證規範。非標準化流程可能難以滿足監管標準和認證，從而限制資金前景和與其他研究機構的合作。然而，由於品質問題或樣本處理不一致而導致的明確特徵的樣本短缺可能會阻礙研究，尤其是針對罕見疾病或特定患者群體的研究。生物庫的成功取決於維持利害關係人的信任，包括捐贈者、研究人員、醫生和監管機構。樣本品質差和缺乏統一性會降低人們對生物庫資源的可靠性和實用性的信心，從而導致參與度、資金和支持的減少。

不同的收集技術可能會導致生物庫內的樣本品質變化，甚至同一生物庫內的樣本品質也會隨時間而變化。標本處理、儲存條件和處理步驟都會影響生物標本的完整性。維護標本元資料的準確和完整記錄，包括收集細節、儲存條件和品質控制參數，對於資料完整性和可追溯性至關重要。然而，人工記錄程序和資料輸入錯誤可能會危及標本資料的準確性。為了保持數據的準確性和可比性，重要的是擁有經過批准的參考材料和標準來驗證分析方法和監測分析性能。然而，無法獲得經過良好表徵的參考材料可能會阻礙標準化樣品品質評估和校準協議的努力。

The rising importance of genomics, personalized medicine, and biotechnology has raised the demand for high-quality biological samples, which are required for research and development. The rise in chronic diseases, combined with the growing need for personalized medicines, has increased the demand for biobanking. Furthermore, increased funding from both the public and commercial sectors, as well as the formation of large-scale biobanks and advances in storage and preservation technology, have all contributed to the market's growth. The integration of biobanking with big data and artificial intelligence for more effective data analysis and usage is also critical to the industry's growth. The Biobanking Market is expected to surpass a revenue of USD 1065.46 Million in 2023 and reach USD 2117.62 Million by 2031.

Furthermore, Modern biobanks incorporate enhanced automation and digitization to improve the efficiency of sample collection, storage, and data management. Cryopreservation and molecular biology procedures have advanced, improving the quality and endurance of stored biological resources. Furthermore, improved bioinformatics and data analytics enable more effective use of biobanked samples for research and clinical applications. Regulatory frameworks have also evolved to ensure ethical standards and data protection, resulting in increased public trust and participation in biobanking efforts. The market is expected to rise with a projectedCAGR of 9.89% from 2024 to 2031.

Biobanking Market: Definition/ Overview

Modern biobanks incorporate enhanced automation and digitization to improve the efficiency of sample collection, storage, and data management. Cryopreservation and molecular biology procedures have advanced, improving the quality and endurance of stored biological resources. Furthermore, improved bioinformatics and data analytics enable more effective use of biobanked samples for research and clinical applications. Regulatory frameworks have also evolved to ensure ethical standards and data protection, resulting in increased public trust and participation in biobanking efforts. This convergence of circumstances establishes biobanking as a critical component in increasing scientific research and healthcare outcomes. Biobanking's future potential is immense and transformational, with significant implications for personalized medicine, genetics, and public health. As biobanks expand, they will increasingly support large-scale research projects by supplying high-quality, diverse biological samples that allow for deeper insights into disease mechanisms, genetic variations, and therapeutic responses. Integration of new technologies such as artificial intelligence and big data analytics will improve the ability to detect biomarkers and design targeted treatments. Furthermore, biobanking can promote global cooperation, increase illness surveillance, and contribute to preventive healthcare measures, resulting in more effective and personalized medical interventions.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Increasing Advancements in Genomics and Precision Medicine Lead the Expansion of the Biobanking Market?

The increasing advancements in genomics and precision medicine significantly drive the expansion of the Biobanking Market. Genomics and precision medicine rely on high-quality biological samples to better understand genetic variants and their consequences for health and illness. Biobanks provide the required infrastructure to store and maintain these samples, making them available for research and therapeutic uses.

The development of targeted therapeutics aims to customize treatments to particular genetic profiles. Extensive research into the genetic basis of diseases is necessary, which is dependent on access to a broad and well-characterized set of biological samples held in biobanks. As more tailored medicines are created, the demand for biobanking services is increasing. Advances in sequencing technologies, such as next-generation sequencing (NGS) and other genomic technologies, have significantly lowered the cost and duration of genetic analysis. Massive amounts of data generated by these technologies must be linked to properly annotated biological samples. Biobanks play an important part in this process because they provide the samples and data required for large-scale genomic studies.

Furthermore, biobanks enhance genomic research and disease knowledge by providing access to large cohorts of samples from a variety of populations. This assistance is critical for determining the genetic basis of diseases, finding biomarkers, and creating predictive models. As genomic research expands, a strong biobanking infrastructure becomes increasingly important. Precision medicine requires the integration of genomic data and clinical information to provide full insights into patient health. Biobanks frequently link biological samples to clinical data, allowing researchers to correlate genetic information with health outcomes. This integration is critical for the development of tailored treatment programs, which increases demand for biobanking services.

Additionally, advances in genomes and precision medicine frequently require regulatory and ethical support. Improved regulatory and ethical frameworks ensure that biological samples are collected, stored, and used appropriately. These frameworks improve public trust and involvement in biobanking, which expands the available sample pool and strengthens the market. Global collaborations and consortia focused on genomics and precision medicine make collaboration and data sharing easier, and they frequently rely on biobanks to share resources. These joint efforts enable large-scale investigations and rapid discoveries, which increases the demand for improved biobanking systems. The rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular ailments highlights the need for broad biobanking to enable research and development of new treatments. The change to customized medicine, which is primarily reliant on genetic and molecular data, demands well-maintained biobanks to supply the essential biological materials.

The increased interest in genomes and precision medicine has prompted significant investment from both commercial and research institutions. This investment supports the creation and growth of biobanking facilities, ensuring that they are equipped with the most up-to-date technologies and best practices to suit the field's evolving demands.

How does Sample Quality and Standardization Hold Back the Biobanking Market?

Irreproducible research findings might be the result of poor sample quality, weakening the credibility of scientific study. Variability and bias in experimental results can occur when samples are contaminated, damaged, or mismanaged during collection, processing, or storage, making it difficult for other researchers to duplicate the findings. Poor sample quality has the potential to jeopardize the integrity of linked data, including clinical, genomic, and omics data. Inaccurate or incomplete data combined with low-quality samples can lead to incorrect conclusions, impeding the growth of scientific knowledge.

Furthermore, biobanks must ensure sample integrity and stability throughout time, as they are tasked with storing samples for extended periods of time, perhaps decades. To guarantee that samples remain viable and representative of the original specimen, storage parameters must be strictly controlled, such as temperature, humidity, and light exposure. Failure to maintain correct storage conditions might cause sample degradation, making them unsuitable for downstream analysis. Inter-laboratory variability might result from a lack of standardization in sample collecting and processing techniques amongst biobanks. variations in the procedures, protocols, and equipment employed by different biobanks might cause variations in sample quality, making it difficult to compare results or combine data from various research.

Additionally, regulatory compliance and accreditation are critical parts of biobanking, with biobanks subject to regulatory restrictions and accrediting standards to ensure they follow ethical, legal, and quality assurance norms. Non-standardized processes might make it difficult to meet regulatory standards and acquire accreditation, limiting funding prospects and collaborations with other research institutes. Researchers rely on biobanks to offer high-quality samples for their studies; yet a lack of well-characterized samples due to quality issues or discrepancies in sample processing might hamper research efforts, particularly for uncommon diseases or specific patient populations. The success of biobanking efforts is dependent on sustaining stakeholder trust, which includes donors, researchers, doctors, and regulatory agencies. Poor sample quality and lack of uniformity can reduce trust in the trustworthiness and utility of biobank resources, leading to decreasing participation, financing, and support.

Different collection techniques within biobanks, or even within the same biobank over time, might result in changes in sample quality. Sample handling, storage conditions, and processing processes all have an impact on biological specimen integrity. Maintaining accurate and thorough documentation of sample metadata, such as collection details, storage conditions, and quality control parameters, is critical for data integrity and traceability. However, human record-keeping procedures and data input errors can jeopardize the accuracy of sample data. The availability of approved reference materials and standards for validating analytical methods and monitoring assay performance is critical for maintaining data correctness and comparability. However, limited access to well-characterized reference materials can stymie efforts to standardize sample quality assessment and calibration protocols.

Category-Wise Acumens

How does the Increasing Demand for Clinical Research Advance the Growth of the Biobanking Market?

The increasing demand for clinical research is fuelling growth in the Biobanking Market. Biobanks serve an important role in precision medicine projects by allowing researchers access to large-scale collections of well-characterized clinical samples such as tissues, blood, and biological fluids, as well as accompanying clinical data. These resources allow for the identification of disease biomarkers, the classification of patient populations, and the development of targeted medicines, increasing the demand for high-quality clinical samples held in biobanks.

Biobanks facilitate biomarker development and validation in clinical research, which is critical for improving illness diagnosis, monitoring therapy efficacy, and predicting patient outcomes. Diverse patient samples are made available for biomarker identification and validation investigations, which helps to translate basic research discoveries into therapeutic applications. Furthermore, biobanks provide researchers and pharmaceutical companies with patient-derived samples for preclinical investigations and biomarker-driven clinical trials.

Furthermore, using well-characterized clinical samples from biobanks, researchers can assess the safety, efficacy, and pharmacokinetics of investigational drugs, identify patient subgroups likely to benefit from treatment, and optimize trial design, thereby improving drug development efficiency and accelerating approval timelines. Biobanks also enhance disease modelling and personalized medicine techniques by allowing researchers access to patient-derived samples to study disease mechanisms, identify therapeutic targets, and design patient-specific treatment regimens. Using human tissues, cell lines, and bodily fluids from biobanks, researchers can mimic disease phenotypes in vitro and test medication responses in patient-derived models, allowing for individualized treatment selection and optimization based on specific patient features.

Additionally, the growing demand for clinical research is driving increased collaboration across biobanks, research institutions, and healthcare organizations to improve data exchange, standardize research protocols, and stimulate cross-disciplinary partnerships. Using shared resources and expertise, researchers can get access to larger and more diversified sample collections, overcome resource constraints, and accelerate scientific discoveries, thereby increasing our understanding of disease pathophysiology and patient treatment. Biobanks follow regulatory criteria and quality assurance standards to assure the ethical collection, storage, and dissemination of clinical samples. Compliance with laws such as Good Clinical Practice (GCP) and the Health Insurance Portability and Accountability Act (HIPAA) boosts confidence among researchers, sponsors, and regulatory bodies, promoting the expansion of the biobanking sector.

The increased emphasis on personalized healthcare, which seeks to provide tailored medical treatments based on unique patient characteristics, increases the demand for high-quality clinical samples and molecular data. Biobanks allow researchers and doctors to examine patient-derived samples for genetic variants, biomarker profiles, and therapy responses, resulting in more accurate diagnoses and focused medicines. High-throughput sequencing, omics technologies, and bioinformatics tools have revolutionized clinical research and biomarker identification. Biobanks use these technologies to undertake extensive molecular profiling of patient samples, detect disease signs, and predict therapy responses, fostering innovation and growth in the biobanking industry.

Will the Rising Utilization Nucleic Acids and Cell Lines Drive the Growth of the Biobanking Market?

The rising utilization of nucleic acids and cell lines in various research and clinical applications is expected to drive the growth of the Biobanking Market. High-throughput sequencing technologies have brought genomic research into the modern era, allowing for complete examination of DNA and RNA materials. Nucleic acids extracted from biobank specimens provide valuable resources for large-scale genomic investigations aiming at understanding disease genetics, finding biomarkers, and discovering therapeutic targets. As genomic research expands, there will be a large increase in demand for high-quality nucleic acid samples from biobanks.

Furthermore, nucleic acid samples are critical in precision medicine initiatives because they allow for the detection of genetic variants linked to disease susceptibility, therapeutic response, and treatment outcomes. Biobanks provide researchers and clinicians with access to vast libraries of well-annotated nucleic acid samples, which enables population-based studies and individualized healthcare interventions. Biobanks aid liquid biopsy research by giving access to archived blood samples and other biological fluids gathered over time from people with cancer and other disorders. Well-characterized nucleic acid samples from biobanks speed up the development and validation of liquid biopsy assays for clinical usage. Cell lines produced from biobank specimens are valuable tools for researching cellular physiology, disease processes, and medication responses in vitro.

Additionally, advances in stem cell biology, genome editing, and tissue engineering have expanded the use of cell lines in regenerative medicine, drug discovery, and disease modelling. Biobanks are repositories of verified and quality-controlled cell lines that help researchers develop cell-based therapeutics for a variety of ailments. Cell lines produced from biobank specimens are commonly used in pharmaceutical research and development to screen drug candidates, investigate pharmacological mechanisms of action, and predict drug toxicity.

Biobanks provide researchers and drug developers with diverse cell line collections covering various tissue types, disease states, and genetic origins, thereby expediting drug development, lowering costs, and increasing preclinical model predictability. Cell lines are also used in regenerative medicine applications such cell treatment, tissue engineering, and organ transplantation. Biobanks are critical in producing stem cell lines, induced pluripotent stem cells (iPSCs), and other cell types for regenerative medicine research and therapeutic use. The ability to bank and disseminate well-characterized and quality-controlled cell lines is critical for improving regenerative medicine therapy, driving market growth in this segment.

Biobanking Market

Report Methodology

Country/Region-wise

How does Advanced Healthcare Infrastructure and Research Funding in North America Boost Up the Biobanking Market?

North America's advanced healthcare infrastructure and robust research funding and investment ecosystem create an enabling environment for biobanking activities. North America is distinguished by cutting-edge healthcare facilities, such as hospitals, clinics, and research institutions, which are outfitted with advanced diagnostic and treatment technologies, providing the infrastructure for conducting biomedical research and clinical studies that require access to patient samples.

The region's interconnected healthcare ecosystem promotes collaboration among healthcare providers, research institutions, and biobanks, allowing clinicians to easily collect and bank biospecimens from patients enrolled in clinical trials or routine healthcare visits. This agreement guarantees a consistent supply of high-quality samples for biobanking programs.

Furthermore, many healthcare organizations in North America have taken a patient-centric approach, encouraging patient participation in research activities, such as sample donation for biobanking purposes. Patient engagement initiatives, such as informed consent processes, community outreach programs, and patient advocacy groups, promote awareness of biobanking and facilitate sample collection efforts. The widespread adoption of electronic health records (EHR) in North America facilitates the integration of clinical and research data, streamlining sample collection and data annotation processes. Biobanks can leverage EHR systems to identify eligible patients, track sample provenance, and link molecular data with clinical outcomes, thereby enhancing the utility of biobank resources for research purposes.

Additionally, regarding research funding and investment, substantial funding is allocated by government agencies in North America, such as the National Institutes of Health (NIH) in the United States and the Canadian Institutes of Health Research (CIHR) in Canada, to support biomedical research and biobanking initiatives. These agencies' research grants and cooperative agreements make it possible to build and expand biobanks, fund infrastructure development, sample collection initiatives, and conduct research projects that use biobank resources. Furthermore, North America receives significant private funding from venture capital firms, philanthropic organizations, and biotechnology corporations interested in supporting biobanking infrastructure and research. Private investment enables biobanks to update their facilities, implement cutting-edge technology, and expand sample collections in response to new research objectives and market demands.

Collaboration between biobanks and pharmaceutical, biotechnology, and diagnostic industries in North America promotes innovation and speeds translational research initiatives. Industry partners may give financial support, technical experience, and access to specialized resources, thereby increasing the value proposition of biobank resources and accelerating the development of novel diagnostics, treatments, and personalized medicine strategies. Furthermore, collaboration between biobanks and academic institutions in North America encourages interdisciplinary research collaborations and knowledge sharing. Academic collaborations provide access to research skills, specialized equipment, and training opportunities, which improve biobank activities and advance scientific discovery in fields such as genomics, precision medicine, and regenerative therapies.

Will the Increasing Healthcare Expenditure and Growing Biotechnology in the Asia-Pacific Region Promote the Biobanking Market Further?

The increasing healthcare spending in the Asia-Pacific region enables investment in healthcare infrastructure, such as the establishment and expansion of biobanking facilities, which require sophisticated infrastructure for sample collection, processing, storage, and distribution, as well as specialised equipment and personnel. Higher healthcare spending allows for the development of cutting-edge biobanking infrastructure, hence supporting market growth.

Healthcare expenditure enables higher funding allocations for research and development (R&D) activities in the Asia-Pacific region, with academic institutions, research organizations, and pharmaceutical companies receiving more resources to conduct biomedical research, drug discovery, and clinical trials. Biobanks play an important role in supporting R&D operations by providing high-quality biological samples, hence generating demand for biobanking services and solutions. The growth of healthcare access in the Asia-Pacific area, driven by increased healthcare spending, creates a growing demand for healthcare solutions suited to individual patients' requirements, including personalized medicine approaches.

Furthermore, biobanks support personalized medicine initiatives by providing biological samples for genomic research, biomarker identification, and pharmaceutical development, which drives market demand. Government initiatives and policies in the Asia-Pacific region encourage healthcare innovation, research collaboration, and technological adoption, with many countries providing incentives and funding to support biobanking infrastructure development, research partnerships, and regulatory compliance. Initiatives like China's Precision Medicine Initiative and Singapore's Biomedical Sciences Initiative seek to improve healthcare innovation and research, hence promoting the expansion of the biobanking industry. Increased healthcare spending drives developments in healthcare services and technologies in the Asia-Pacific area. Precision medicine, genetic research, and personalized healthcare approaches are becoming increasingly popular, need access to large amounts of biological samples and data. Biobanks play an important role in allowing these advances by supplying broad and well-characterized sample sets, which drive market growth.

Additionally, emerging markets and potential in the Asia-Pacific area, such as China, India, and South Korea, are driven by increased healthcare expenditure, leading to demand for biobanking solutions and infrastructure. These countries, with their huge and diverse populations, genetic variety, and rising burden of chronic diseases, present enormous prospects for biobanking services and research collaborations. Biobanks serve a crucial role in drug discovery and development efforts by biotechnology companies in the Asia-Pacific area by giving access to varied biological samples. These activities include target identification, lead optimization, and preclinical testing.

Precision medicine projects in the Asia-Pacific area are highlighted, with the goal of tailoring medical therapies to individual patients' genetic makeup and illness profiles, with biobanks serving as critical resources for genomic analysis, biomarker development, and tailored treatment options. Biotechnology companies in Asia-Pacific are also looking into regenerative medicine approaches such as cell therapy, tissue engineering, and organ transplantation, with biobanks helping with research by providing stem cells, tissue samples, and other biological materials for experimentation and clinical applications.

Competitive Landscape

The Biobanking Market's competitive landscape includes a diversified mix of rising startups, specialty service providers, and regional biobanks. These firms frequently focus on specialized services, such as niche sample kinds, innovative storage systems, or specific disease regions, to meet the changing needs of researchers and pharmaceutical corporations. Furthermore, technical developments in sample processing, storage, and data management have resulted in the emergence of creative solution providers who offer unique platforms and services, upsetting established biobanking models. Regional biobanks, especially in emerging economies, add to the competitive landscape by leveraging local expertise, cooperation with academic institutions, and government backing to establish biobanking infrastructure suited to regional healthcare requirements.

Some of the prominent players operating in the Biobanking Market include:

Tecan Group Ltd, Lonza, PHC Holdings Corporation, Thermo Fisher Scientific Inc., Hamilton, Brooks Automation, Qiagen N.V., TTP Labtech Ltd, Becton, Dickinson and Company, Merck & Co., Avantor, Inc., Cryoport, Inc., Azenta, Inc.

Latest Developments

In April 2023, Merck & Co. has agreed to acquire Prometheus Biosciences for about $10.8 billion, in a deal intended to bolster the buyer's immunology drug pipeline as it faces loss of exclusivity for some of its best-selling products over the next few years. Based in San Diego, Prometheus develops precision drugs and companion diagnostics for immune-mediated diseases. The company's lead candidate, PRA023, is a humanized monoclonal antibody indicated for autoimmune conditions that include ulcerative colitis (UC), Crohn's disease (CD), and Systemic Sclerosis-associated Interstitial Lung Disease.

In October 2022, LabVantage Solutions and Biomax Informatics Merge to Create Innovative Capabilities for the Life Science and Bio Manufacturing Industries. LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, and Biomax Informatics AG, a software solutions and services provider for efficient decision-making and knowledge management at the intersection of life sciences, healthcare, and information technologies. Customers will now have more confidence in mission-critical projects that depend on the contextualisation of scientific data.

1 INTRODUCTION OF GLOBAL BIOBANKING MARKET

1.1 Introduction of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL BIOBANKING MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL BIOBANKING MARKET, BY TYPE

5.1 Overview
5.2 Equipment
5.3 Consumables
5.4 Services
5.5 Software

6 GLOBAL BIOBANKING MARKET, BY APPLICATION

6.1 Overview
6.2 Life Science Research
6.3 Regenerative Medicine
6.4 Clinical Research
6.5 Therapeutic Applications

7 GLOBAL BIOBANKING MARKET, BY SAMPLE TYPE

7.1 Overview
7.2 Blood Products
7.3 Human Tissues
7.4 Nucleic Acids
7.5 Cell Lines
7.6 Biological Fluids
7.7 Human Waste Products

8 GLOBAL BIOBANKING MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL BIOBANKING MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Tecan Group Ltd
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Lonza
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 PHC Holdings Corporation
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Thermo Fisher Scientific Inc.
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Hamilton
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Brooks Automation
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Qiagen N.V.
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 TTP Labtech Ltd
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Cryoport, Inc.
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Azenta, Inc.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments